Work

A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Year: 2014

Type: article

Source: Blood

DOI: 10.1182/blood.v124.21.1725.1725

Authors: Ian Flinn, Nancy L. Bartlett, Kristie A. Blum, Kirit M Ardeshna, Ann LaCasce, Christopher R. Flowers, Andrei R. Shustov, Kenneth Thress, Fred Zheng, Jeffery Skolnik, Jonathan W. Friedberg

Institutions: Sarah Cannon, Tennessee Oncology, Washington University in St. Louis, The Ohio State University, University College Hospital, Sarah Cannon Research Institute, Dana-Farber Cancer Institute, Winship Cancer Institute, University of Washington Medical Center, AstraZeneca (United States), GlaxoSmithKline (United States), University of Rochester

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2147968449

FWCI: 0.438

Cites:

Cited by: 7

Related to: 10